Updated just now · Live
Stock analysis, price data, and AI-powered insights for Definium Therapeutics Inc (DFTX).
Definium Therapeutics Inc operates in the Pharmaceuticals sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for DFTX.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). DFTX Stock Intelligence Report. [stoxpulse.com/stocks/dftx]
Disclaimer: The information on this page about Definium Therapeutics Inc (DFTX) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Definium Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Definium Therapeutics Announces New Employee Induc...
1d ago
Enveric BioSciences Surges Over 90%, Other Psyched...
1d ago
StoxPulse AI results for DFTX: Pulse Score 51/100. Primary sentiment trends from 10 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$2.31B
P/E Ratio
—
EPS
$-0.78
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Definium Therapeutics Announces New Employee Inducement Grants
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
Reported Earlier, Definium Therapeutics Issued The Statement Supporting The Newly Signed White House Executive Order Aimed At Accelerating Research, Development, And Responsible Access To Innovative Treatments For Serious Mental Illness, Including Emerging Psychedelic Medical Treatments
Definium Therapeutics supports White House executive order on mental health innovation, committed to developing psychedelic treatments for mental health
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones
Stifel Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $30
Shares of psychedelic companies are trading higher following reports suggesting that President Trump will sign an executive order that would further U.S. research into a drug used abroad, ibogaine, to treat PTSD.